Rx industry and campaign finance reform
The pharmaceutical industry-funded Citizens for Better Medicare advocacy group is cited as an example of disguised electioneering during Sept. 8 oral arguments before the Supreme Court over the McCain/Feingold campaign finance reform law. Wilmer, Cutler & Pickering Partner Seth Waxman, representing Sen. John McCain (R-Ariz.) in supporting the law, noted that CBM described itself as "a group of concerned seniors and companies and associations concerned about Medicare." It was "in fact funded almost exclusively by PhRMA and the companies that make up PhRMA," he continued. The association ran 23,867 "issue ads" about Medicare from Jan. 1 until Sept. 4 "and not a single one mentioned a candidate." In the last 60 days before the elections, "they ran 10,876 ads, all mentioning candidates." Then, "on election day, they stopped cold"...
You may also be interested in...
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”